Study Type
Interventional - Drug
completed
EPIC STEMI was a randomized, double-blind, placebo controlled parallel group clinical trial evaluating the effects of acute treatment with a PCSK9 inhibitor, alirocumab, versus placebo, on low-density lipoprotein (LDL) in 100 high-risk patients presenting with STEMI and referred for primary PCI.
The objective was to determine the effect of acute, rapid lowering of LDL cholesterol with alirocumab added to high dose statin therapy in patients with STEMI undergoing primary PCI.
The hypothesis was that in patients with STEMI undergoing primary PCI, rapid lowering of LDL cholesterol with a PCSK9 inhibitor (alirocumab) – initiated in the acute setting pre-PCI – will favourably affect LDL cholesterol concentrations compared with placebo.
EPIC STEMI, TCT 2022 (download PDF)Study Design
A randomized, double-blind, placebo RCT
NO. of Countries
1
NO. of Sites
1
NO. of Participants
100
Study Period
2019 - 2021
Sponsor
PHRI
Shamir Mehta
Senior Scientist
Shamir Mehta
Senior Scientist
Shamir Mehta is a Senior Scientist with the Acute Coronary Syndrome and Interventional Cardiology research program at PHRI, a Professor of Medicine at McMaster University, and Director of the Interventional Cardiology program at Hamilton Health Sciences. His research focuses on the role and timing of invasive therapies in patients with acute ischemic heart disease, and the evaluation of novel antiplatelet and anticoagulant therapies in these patients.
He has led several large pragmatic randomized trials evaluating invasive interventional strategies in patients with acute coronary syndromes. He has also lead multinational randomized trials evaluating novel antiplatelet and anticoagulant therapies to improve outcomes in patients experiencing a heart attack.
Shamir Mehta has published 127 original research papers in several medical journals including The New England Journal of Medicine, The Lancet, JAMA, and Circulation. His success in research has earned him a coveted Canada’s Top 40 under 40TM award in 2004, and he has received a Canadian Institutes of Health Research New Investigator Career Award.
Tara McCready
Program Director
Tara McCready
Program Director
Tara McCready, PhD, oversees a variety of collaborative programs at PHRI, and serves as Project Manager for PHRI research studies and registries.
She was recruited to PHRI as a Program Director for the Canadian Network and Centre for Trials Internationally (CANNeCTIN), a national network funded by the CIHR/CFI Clinical Research Initiative program to improve the prevention and treatment of cardiac and vascular diseases and diabetes.
Previously the Executive Director of the Canadian Maternal, Infant, Child and Youth Research Network, Tara holds a PhD in Biochemistry and a MBA in Technology Commercialization from the University of Alberta.
Sanofi
VIDEO: Shamir Metha on EPIC STEMI with C. Michael Gibson at TCT 2022
